{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-257298","form_type":"8-K/A","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.988571+00:00","generated_at":"2026-05-17T01:21:16.279003+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Wave Life Sciences reports positive WVE-007 target engagement: up to 85% Activin E reduction; WVE-008 candidate selected","bullets":["WVE-007 Activin E reductions: 85% (400mg), 75% (240mg), 56% (75mg) at day 29; Cohort 1 durable through 6 months, supporting 1-2x/year dosing.","WVE-007 safe/well-tolerated; DMC cleared dose expansion to 600mg and beyond. Body composition/weight data updates expected starting 4Q2025.","WVE-008 selected as PNPLA3-I148M RNA editing candidate for liver disease; CTA filing expected in 2026. Estimated 9M homozygous patients in US/EU.","WVE-006 AATD cohort 3 (600mg) now underway; previously restored 13 µM total AAT with 64% M-AAT. Multidose data expected 1Q2026.","Platform data: single oligonucleotide can simultaneously edit and silence two targets (LDLR up, PCSK9 down) in preclinical models."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-257298","json":"https://secwatch.observer/filing/0001193125-25-257298.json","markdown":"https://secwatch.observer/filing/0001193125-25-257298.md","text":"https://secwatch.observer/filing/0001193125-25-257298.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312525257298/0001193125-25-257298-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312525257298/d59691d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:21:16.279003+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}